Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10708821 | 1.00 | LMNA (0.31) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL11982744 | 1.00 | LMNA (0.31) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL4870579 | 1.00 | LMNA (0.31) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL4732116 | 1.00 | LMNA (0.31) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL4732950 | 1.00 | LMNA (0.31) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL5050945 | 1.00 | LMNA (0.31) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL4867921 | 0.98 | THRB (0.30) | — | |
| SCHEMBL10711465 | 0.98 | THRB (0.30) | — | |
| SCHEMBL10554776 | 0.98 | THRB (0.30) | — | |
| SCHEMBL4795196 | 0.98 | THRB (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1455663-A | Novel aerosol formulation containing polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | CN | claimed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| EP-4735260-A1 | EPOXY-BASED UV-VIS-CURABLE COMPOSITIONS | Sicpa Holding SA (CH) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025003227-A1 | EPOXY-BASED UV-VIS-CURABLE COMPOSITIONS | SICPA HOLDING SA (CH) | 2025-01-02 | — | — | WO | disclosed |
| US-12147012-B2 | Optical element and method for manufacturing the same | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2024-11-19 | — | — | US | disclosed |
| CN-113574422-B | Optical element and method for manufacturing the same | 松下知识产权经营株式会社 | 2023-10-13 | — | — | CN | disclosed |
| EP-3627212-B1 | CONTACT LENS COMPOSITION, AND CONTACT LENS AND METHOD FOR MANUFACTURING SAME | TORAY INDUSTRIES (JP) | 2023-07-26 | — | — | EP | disclosed |
| US-11444251-B2 | Organic electroluminescent element | MERCK PATENT GMBH (DE) | 2022-09-13 | — | — | US | disclosed |
| WO-2022163199-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT, METHOD FOR PRODUCING SAME, LIGHTING DEVICE PROVIDED WITH SAME, DISPLAY DEVICE AND PRINTED MODEL | コニカミノルタ株式会社 | 2022-08-04 | — | — | WO | disclosed |
| CN-113524815-B | Waterproof elastic fabric and preparation method thereof | 上海沙驰服饰有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20020195585-A1 | Liquid crystalline materials containing perfluoroalkyl and alkenyl tail groups | CITIZEN FINEDEVICE CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
| EP-1042355-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2000-10-11 | — | — | EP | disclosed |
| US-6060626-A | REACTING A FLUORINATED HYDROXY COMPOUND AND A CARBONYL COMPOUND IN PRESENCE OF ETHERIFICATION CATALYST IN HYDROGEN ATOMOSPHERE TO PRODUCE FLUORINE CONTAINING ETHER | KAO CORPORATION (JP) | 2000-05-09 | — | — | US | disclosed |
| US-6046348-A | Silane compound, method for making the same, and electrophotographic photoreceptor | FUJI XEROX CO., LTD. (JP) | 2000-04-04 | — | — | US | disclosed |
| US-6002048-A | Fluorine-containing ether compound and gelling agent containing the same | KAO CORPORATION (JP) | 1999-12-14 | — | — | US | disclosed |
| WO-1999033855-A1 | 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-08 | — | — | WO | disclosed |
| EP-0837085-A1 | POLYCARBONATE-BASE POLYMER, PRODUCTION PROCESS, RESIN COATING FLUID PREPARED THEREFROM, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR PREPARED THEREFROM | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1998-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11444251-B2 | Organic electroluminescent element | VDAC1, EPCAM, LAGE3 | LMNA 1178/4885ALDH1A1 2452/4885HSD17B10 2587/4885 |
| US-20020195585-A1 | Liquid crystalline materials containing perfluoroalkyl and alkenyl tail groups | ELOVL3, LPCAT1, FABP4 | LMNA 92/4885ALDH1A1 2032/4885HSD17B10 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.